DOP2002000337A - Inhibidores de metaloproteinasas de matriz basados en pirimidinas fusionadas - Google Patents

Inhibidores de metaloproteinasas de matriz basados en pirimidinas fusionadas

Info

Publication number
DOP2002000337A
DOP2002000337A DO2002000337A DO2002000337A DOP2002000337A DO P2002000337 A DOP2002000337 A DO P2002000337A DO 2002000337 A DO2002000337 A DO 2002000337A DO 2002000337 A DO2002000337 A DO 2002000337A DO P2002000337 A DOP2002000337 A DO P2002000337A
Authority
DO
Dominican Republic
Prior art keywords
alkyl
hydrogen
fusioned
pyrimidins
inhibitors based
Prior art date
Application number
DO2002000337A
Other languages
English (en)
Inventor
William Glen Harter
Jie Jack Li
Kevon Ray Shuler
Daniel Fred Ortwine
Wen-Song Yue
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of DOP2002000337A publication Critical patent/DOP2002000337A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Son inhibidores selectivos de MMP-13 las pirimidinonas fusionadas de formula. o una sal farmacéuticamente aceptable de las mismas; en donde: W, junto con los átomos de carbono a los cuales está unido, forma un dirradical anular de 5 miembros X es o, s, So, so2, NR5, ó CH2 A es -C- ó -S-; B es O o bien NR5 o bien A y B son tomados juntos para formar -CC-; R, R4, y R5 son hidrógeno, alquilo, alquenilo, alquinilo, CH2-ari1o, CH2-cic1oa1qui1o, alcanoílo C1-C6, ó CH2 -heteroari1o; R2 y R3 son hidrógeno, alquilo, alquenilo, alquinilo, CN, N02, NR4R5, CH2-cic1oa1qui1o, CH2-ari1o, ó CH2 -heteroari1o; R2 puede ser, además, halo; n es un número entero de O a 5; y R4 y R5, cuando son tomados junto con el nitrógeno al cual están unidos, completan un anillo de 3 a 8 miembros que contiene átomos de carbono y contiene opciona1meite o, S, o bien N, y está sustituido o sin sustituir; con la salvedad de que R y R3 no estén ambos seleccionados de hidrógeno y alquilo C1-C6.
DO2002000337A 2001-02-14 2002-02-01 Inhibidores de metaloproteinasas de matriz basados en pirimidinas fusionadas DOP2002000337A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26875601P 2001-02-14 2001-02-14

Publications (1)

Publication Number Publication Date
DOP2002000337A true DOP2002000337A (es) 2002-08-15

Family

ID=23024328

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2002000337A DOP2002000337A (es) 2001-02-14 2002-02-01 Inhibidores de metaloproteinasas de matriz basados en pirimidinas fusionadas

Country Status (15)

Country Link
US (1) US20030004172A1 (es)
EP (1) EP1370562A1 (es)
JP (1) JP2004518732A (es)
BR (1) BR0207216A (es)
CA (1) CA2433778A1 (es)
DO (1) DOP2002000337A (es)
GT (1) GT200200017A (es)
HN (1) HN2002000029A (es)
MX (1) MXPA03004926A (es)
PA (1) PA8538301A1 (es)
PE (1) PE20020957A1 (es)
SV (1) SV2003000882A (es)
TN (1) TNSN02009A1 (es)
UY (1) UY27159A1 (es)
WO (1) WO2002064598A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2002000334A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
EP2363396A1 (en) * 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
MXPA04002537A (es) 2001-10-12 2004-05-31 Warner Lambert Co Alquinos como inhibidores de metaloproteinasa de matriz.
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
MXPA05000754A (es) * 2002-07-17 2005-04-19 Warner Lambert Co Combinacion de un inhibidor carboxilico alosterico de la metaloproteinasa de matriz-13 con celecoxib o valdecoxib.
EP1531904A1 (en) * 2002-07-17 2005-05-25 Warner-Lambert Company LLC Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
BR0312727A (pt) * 2002-07-17 2005-04-19 Warner Lambert Co Combinação de um inibidor alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
CA2497658A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
WO2004014869A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
MXPA05001784A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de isoquinolina como inhibidores de metaloproteinasa de matriz.
AU2003249477A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
WO2004014365A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
MXPA05001783A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
WO2004014921A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors
MXPA05001603A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
MXPA05001786A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
WO2004014384A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
JP2008094846A (ja) * 2003-01-29 2008-04-24 Takeda Chem Ind Ltd チエノピリミジン化合物およびその用途
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US7570259B2 (en) 2004-06-01 2009-08-04 Intel Corporation System to manage display power consumption
US7576098B2 (en) 2004-12-08 2009-08-18 Bristol-Myers Squibb Company Heterocyclic compounds as inhibitors of factor VIIa
CA2644996A1 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
EA200900330A1 (ru) 2006-08-23 2009-08-28 Ньюроджен Корпорейшн Аналоги 2-феноксипиримидинона
WO2008070529A2 (en) * 2006-12-01 2008-06-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
EP1939197A1 (en) 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
WO2008138126A1 (en) * 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
AR077898A1 (es) 2009-08-26 2011-09-28 Nycomed Gmbh Metilpirrolopirimidincarboxamidas
MX370976B (es) * 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
EA201600318A1 (ru) 2013-10-07 2016-09-30 Байер Фарма Акциенгезельшафт Циклические тиеноурацилкарбоксамиды и их применение
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
AR106472A1 (es) * 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
US20170166582A1 (en) 2015-11-25 2017-06-15 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
EP3380478B1 (en) 2015-11-25 2020-12-23 Gilead Apollo, LLC Ester acc inhibitors and uses thereof
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
CN108347939B (zh) 2015-11-25 2021-09-28 吉利德阿波罗公司 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
SG11201902588PA (en) 2016-09-23 2019-05-30 Bayer Ag N3-Cyclically Substituted Thienouracils And Use Thereof
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
CN110183464B (zh) * 2019-05-31 2021-08-31 淮阴工学院 一种抗癌化合物艾斯替尼及其合成方法和应用
KR102649886B1 (ko) * 2021-07-21 2024-03-22 충남대학교산학협력단 신규한 피리미딘-4-온 화합물 및 이를 포함하는 항암제 조성물
EP4568971A1 (en) * 2022-08-09 2025-06-18 Vanderbilt University Antagonists of 5-hydroxytryptamine receptor subtype 2b

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155665A (en) 1961-04-26 1964-11-03 Searle & Co 4, 6-dialkyl-5, 7-diketothiazolo [4, 5-d] pyrimidine-2-carboxylic acid and derivatives thereof
US3277093A (en) 1965-08-02 1966-10-04 Searle & Co (optionally-2-substituted) 4-halophenyl-5, 7-diketo-6-alkylthiazolo[4, 5-d]pyrimidines
GB8601371D0 (en) 1986-01-21 1986-02-26 Beecham Group Plc Compounds
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US6048863A (en) * 1994-04-19 2000-04-11 Takeda Chemical Industries, Ltd. Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use
WO1996014319A1 (en) * 1994-11-08 1996-05-17 Takeda Chemical Industries, Ltd. Thienopyridine or thienopyrimidine derivatives and their use
US5792767A (en) * 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
CN1066448C (zh) * 1996-06-06 2001-05-30 株式会社大塚制药工场 酰胺衍生物
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6166019A (en) * 1998-07-16 2000-12-26 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
US6300334B1 (en) * 1998-08-28 2001-10-09 Astrazeneca Ab Thieno[2,3-d]pyrimidine-2,4-diones
DE19940494C1 (de) * 1999-08-26 2001-02-15 Ibfb Gmbh Privates Inst Fuer B Mehrcyclische Pyrimidin-2,4(1H,3H)-dione mit funktionalisierten Alkylresten in 1- und/oder 3-Position, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen
PA8539501A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US20050004111A1 (en) * 2003-01-03 2005-01-06 Aventis Pharma Deutschland Gmbh Selective MMP-13 inhibitors

Also Published As

Publication number Publication date
MXPA03004926A (es) 2005-02-14
HN2002000029A (es) 2003-02-14
GT200200017A (es) 2002-11-15
EP1370562A1 (en) 2003-12-17
TNSN02009A1 (fr) 2005-12-23
PE20020957A1 (es) 2002-11-08
WO2002064598A1 (en) 2002-08-22
UY27159A1 (es) 2002-09-30
JP2004518732A (ja) 2004-06-24
US20030004172A1 (en) 2003-01-02
BR0207216A (pt) 2004-03-09
PA8538301A1 (es) 2002-09-17
SV2003000882A (es) 2003-01-13
CA2433778A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
PA8538301A1 (es) Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas
ECSP034691A (es) Inhibidores de piridina de metaloproteinasas de la matriz
PA8538401A1 (es) Pirimidinas inhibidoras de metaloproteinasas de matriz
WO2003068750A1 (en) Jnk inhibitor
CY1112108T1 (el) Αναστολεις ιου ηπατιτιδας c
ES2186821T3 (es) Derivados de 6- bencil- 2h-piridazin-3-ona, su preparacion y s u uso como inhibidores de la prostaglandin-g/h sintasa i y ii (cox i y cox ii).
UA39099C2 (uk) Циклічні азотовмісні похідні, суміш їх ізомерів або окремі ізомери, або їх солі
ES2137486T3 (es) Derivados de 9-hidroxi-pirido(1,2-a)pirimidin-4-ona-eter.
EP1295867A4 (en) BIPHENYL COMPOUND
AR027218A1 (es) Inhibicion de polimerizacion de monomeros insaturados
ES2191985T3 (es) S-oxido de tetrahidrotiopirano feniloxazolidinonas.
BG102647A (en) Acyclic nucleoside derivatives
GB2331987B (en) Polycyclic sulphamate inhibitors of oestrone sulphatase
GB2331988B (en) Polycyclic sulphamate inhibitors or oestrone sulphatase
ES2194102T3 (es) Nuevas n-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
CY1117806T1 (el) Διαταξη ελατηριου αεριου με προστατευτικο χιτωνιο που τοποθετειται πριν το βαψιμο
CO5011097A1 (es) Derivados de 8-azabiciclo [3.2.1]octan-3-metanamina .
CO5080758A1 (es) DERIVADOS DE 3-(2-oxo-[1,3´]BIPIRROLODINIL-3-ILIDENMETIL
TR199701298T1 (xx) Tetralinler.
AR027349A1 (es) Derivados de amidas heterociclicas
CO5261576A1 (es) Compuestos
ATE282608T1 (de) Chinoxalindionen
EA199900684A1 (ru) Производные иминоазаантрациклинона для лечения амилоидоза
KR960703595A (ko) 항우울제(antidepressant)
DK0725776T3 (da) 3-Aryl-4-alkyl- og 4,5-dialkyl-4H-1,2,4-triazoler anvendelige som hukommelsesforbedrende midler